CD8A and cancer: Our results reveal that cDC1s play a role in ADA responses, highlighting the challenge of targeting these cells with a biotherapeutic approach for cancer immunotherapy due to their recently identified function in processing and presenting antigens not only to CD8+ T cells, but also to CD4+ T cells that function to enhance humoral immunity.